Patents by Inventor Roy Macfarlane Pollock

Roy Macfarlane Pollock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200030355
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: January 16, 2019
    Publication date: January 30, 2020
    Inventors: Christine KLAUS, Maria Alejandra RAIMONDI, Scott Richard DAIGLE, Roy MacFarlane POLLOCK, Vivek CHOPRA
  • Patent number: 10525074
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 7, 2020
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Publication number: 20190083521
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2015
    Publication date: March 21, 2019
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock
  • Publication number: 20180028552
    Abstract: The present disclosure relates to a combination of an inhibitor of human histone methyltransferase DOT1L, such as EPZ-5676 or salts thereof, and one or more DNMT inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: February 1, 2016
    Publication date: February 1, 2018
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock, Vivek Chopra
  • Publication number: 20170232030
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 17, 2017
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock, Vivek Chopra
  • Publication number: 20170080010
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 23, 2017
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Patent number: 9446064
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Publication number: 20160045531
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock
  • Publication number: 20140323421
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 30, 2014
    Applicant: EPIZYME, INC.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Patent number: 8580762
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: November 12, 2013
    Assignee: Epizyme, Inc.
    Inventors: Edward James Olhava, Richard Chesworth, Kevin Wayne Kuntz, Victoria M. Richon, Roy Macfarlane Pollock, Scott Richard Daigle